Kevin Mange, MD, Msce
About Kevin Mange, MD, Msce
Kevin Mange, MD, Msce, serves as the Senior Vice President and Head of Clinical Development at Insmed Incorporated, where he leads the development of gene therapy platforms for rare diseases. He has held various leadership roles in clinical development across multiple organizations, including Novartis and Sanofi, and has a strong background in medicine and clinical epidemiology.
Work at Insmed
Kevin Mange currently serves as the Senior Vice President and Head of Clinical Development at Insmed Incorporated. He has held this position since 2019, contributing to the company's clinical strategies and development initiatives. Prior to this role, he was also the SVP, Head of Clinical Development and Medical Affairs at Insmed from 2018 to 2019. In his current role, he is responsible for representing clinical development strategies to the Board of Directors, integrating insights from medical experts and patients.
Education and Expertise
Kevin Mange earned his Doctor of Medicine (MD) degree from Thomas Jefferson University, where he studied from 1988 to 1992. He also holds a Bachelor of Science (BS) in Chemistry/Biology, graduating cum laude from Ursinus College in 1988. Additionally, he obtained a Master of Science in Clinical Epidemiology (MSCE) from the University of Pennsylvania School of Medicine, completing his studies from 1997 to 1999. His educational background supports his expertise in clinical development and medical affairs.
Background
Kevin Mange has extensive experience in clinical development and medical affairs within the pharmaceutical industry. He worked at Novartis as Vice President from 2004 to 2013, focusing on Clinical Development & Medical Affairs. He also held the position of Global Project Head & Vice President for Rare Diseases at Sanofi from 2017 to 2018. Prior to his industry roles, he practiced medicine at various institutions, including the Hospital of the University of Pennsylvania and Beth Israel Deaconess Medical Center/Harvard Medical School.
Achievements
Throughout his career, Kevin Mange has led the development of a new gene therapy platform that focuses on deimmunized proteins for rare diseases across infectious, respiratory, and immunological therapeutic areas. He has experience in rapidly initiating innovative clinical development programs that have received significant health authority designations. His leadership in clinical development has been instrumental in advancing therapeutic strategies in the pharmaceutical sector.